Maija Hollmen
Overview
Explore the profile of Maija Hollmen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turpin R, Peltonen K, Rannikko J, Liu R, Kumari A, Nicorici D, et al.
Oncoimmunology
. 2025 Feb;
14(1):2466305.
PMID: 39960413
Tumor-resident immune cells play a crucial role in eliciting anti-tumor immunity and immunomodulatory drug responses, yet these functions have been difficult to study without tractable models of the tumor immune...
2.
Wolf S, Madanchi M, Turko P, Hollmen M, Tugues S, von Atzigen J, et al.
Nat Commun
. 2024 Dec;
15(1):10784.
PMID: 39737964
Secondary lymphedema is a common sequel of oncologic surgery and presents a global health burden still lacking pharmacological treatment. The infiltration of the lymphedematous extremities with CD4T cells influences lymphedema...
3.
Schmauch E, Ojanen J, Galani K, Jalkanen J, Harju K, Hollmen M, et al.
Nucleic Acids Res
. 2024 Dec;
53(1.
PMID: 39656909
Single-nuclei RNA sequencing remains a challenge for many human tissues, as incomplete removal of background signal masks cell-type-specific signals and interferes with downstream analyses. Here, we present Quality Clustering (QClus),...
4.
Maaniitty E, Sinisilta S, Jalkanen J, Vasankari T, Biancari F, Gunn J, et al.
Int J Cardiol Cardiovasc Risk Prev
. 2024 Aug;
22:200307.
PMID: 39091640
Background: Systemic inflammation has a critical role in the development of symptomatic coronary artery disease (CAD). Identification of inflammatory pathways may provide a platform for novel therapeutic approaches. We sought...
5.
Maaniitty E, Jalkanen J, Sinisilta S, Gunn J, Vasankari T, Biancari F, et al.
Sci Rep
. 2024 Jul;
14(1):17269.
PMID: 39068298
Chronic inflammation plays a crucial role in coronary artery disease (CAD), but differences in specific cytokine profiles between acute coronary syndrome (ACS) and stable CAD remain unknown. We investigated cytokine...
6.
Koivula T, Lempiainen S, Neuvonen J, Norha J, Hollmen M, Sundberg C, et al.
Front Immunol
. 2024 Jul;
15:1394420.
PMID: 38979417
Background: Mobilization of certain immune cells may improve the ability of the immune system to combat tumor cells, but the effect of acute exercise on mobilizing immune cells has been...
7.
Rannikko J, Hollmen M
Br J Cancer
. 2024 Jun;
131(4):627-640.
PMID: 38831013
Tumour-associated macrophages (TAMs) sustain a tumour-supporting and immunosuppressive milieu and therefore aggravate cancer prognosis. To modify TAM behaviour and unlock their anti-tumoural potential, novel TAM-reprogramming immunotherapies are being developed at...
8.
Linna-Kuosmanen S, Schmauch E, Galani K, Ojanen J, Boix C, Ord T, et al.
Cell Rep Med
. 2024 May;
5(5):101556.
PMID: 38776872
Cardiovascular disease plays a central role in the electrical and structural remodeling of the right atrium, predisposing to arrhythmias, heart failure, and sudden death. Here, we dissect with single-nuclei RNA...
9.
Turpin R, Liu R, Munne P, Peura A, Rannikko J, Philips G, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38604809
Background: Combining cytotoxic chemotherapy or novel anticancer drugs with T-cell modulators holds great promise in treating advanced cancers. However, the response varies depending on the tumor immune microenvironment (TIME). Therefore,...
10.
Viikinkoski E, Aittokallio J, Lehto J, Ollila H, Relander A, Vasankari T, et al.
J Cardiothorac Vasc Anesth
. 2024 Jan;
38(3):709-716.
PMID: 38220516
Objectives: Cardiac surgery induces systemic inflammatory response syndrome (SIRS), leading to higher morbidity and mortality. There are no individualized predictors for worse outcomes or biomarkers for the multifactorial, excessive inflammatory...